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Polygenic risk score analysis revealed shared
genetic background in attention deficit
hyperactivity disorder and narcolepsy
Nagahide Takahashi 1,2,8, Tomoko Nishimura 1,2, Taeko Harada1,2, Akemi Okumura1,2, Damee Choi1,2,
Toshiki Iwabuchi1,2, Hitoshi Kuwabara3, Shu Takagai4, Yoko Nomura1,5, Jeffrey. H. Newcorn6, Nori Takei1,2,7 and
Kenji J. Tsuchiya1,2
Abstract
Attention deficit hyperactive disorder (ADHD) is a highly heritable neurodevelopmental disorder, and excessive
daytime sleepiness is frequently observed in ADHD patients. Excessive daytime sleepiness is also a core symptom of
narcolepsy and essential hypersomnia (EHS), which are also heritable conditions. Psychostimulants are effective for the
symptomatic control of ADHD (primary recommended intervention) and the two sleep disorders (frequent off-label
use). However, the common biological mechanism for these disorders has not been well understood. Using a
previously collected genome-wide association study of narcolepsy and EHS, we calculated polygenic risk scores (PRS)
for each individual. We investigated a possible genetic association between ADHD and narcolepsy traits in the
Hamamatsu Birth Cohort for mothers and children (HBC study) (n= 876). Gene-set enrichment analyses were used to
identify common pathways underlying these disorders. Narcolepsy PRS were significantly associated with ADHD traits
both in the hyperactivity domain (e.g., P-value threshold < 0.05, β [SE], 5.815 [1.774]; P= 0.002) and inattention domain
(e.g., P-value threshold < 0.05, β [SE], 5.734 [1.761]; P= 0.004). However, EHS PRS was not significantly associated with
either domain of ADHD traits. Gene-set enrichment analyses revealed that pathways related to dopaminergic
signaling, immune systems, iron metabolism, and glial cell function involved in both ADHD and narcolepsy. Findings
indicate that ADHD and narcolepsy are genetically related, and there are possible common underlying biological
mechanisms for this relationship. Future studies replicating these findings would be warranted to elucidate the
genetic vulnerability for daytime sleepiness in individuals with ADHD.
Introduction
Attention deficit hyperactive disorder (ADHD) is a
common neurodevelopmental disorder with onset
occurring in childhood. Genetic factors play an important
role in the development of ADHD, with a heritability of
up to 75%1. Both rare and common genetic variants have
been associated with ADHD. Recent genome-wide asso-
ciation studies (GWAS) have identified several genomic
regions associated with ADHD, with a modest contribu-
tion of common variants to its development2.
Recently, based on a polygenic model for complex dis-
orders, polygenic risk scores (PRS) have been calculated
and widely used to explain the genetic liability of indivi-
duals for certain diseases or phenotypes, using common
genetic variants tested in GWAS3. PRS can also be used to
examine the genetic association between two different
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diseases or phenotypes. To date, the association of ADHD
PRS has been reported with depressive symptoms4, body
mass index5, substance use disorder6, and educational
attainment7, but no examination has thus far been con-
ducted with sleep disorders. Nevertheless, patients with
ADHD frequently show excessive daytime sleepiness
(EDS)8. Narcolepsy is characterized by EDS with or
without cataplexy (sudden and uncontrollable muscle
weakness or paralysis triggered by a strong emotion),
hypnagogic hallucinations, and sleep paralysis (vivid and
dream-like hallucinations and muscle paralysis while
falling asleep), and disturbed nocturnal sleep. The pre-
valence of ADHD in individuals with narcolepsy is
(~35%)9 higher than in the general population (~5%)10.
Furthermore, psychostimulants, such as methylphenidate,
are effective for controlling symptoms of ADHD (first-line
approved treatment) and narcolepsy11 (frequently used
off-line with good effects). However, the nature of the
relationship between the two conditions and the possi-
bility that underlying biological mechanisms connect the
two have not been elucidated yet.
One recent study conducted in Japan demonstrated that
the relative risk of narcolepsy in affected first-degree
family members is 10- to 40-fold higher than in the
general population, suggesting that genetic factors play an
important role in this disease12. Of note, the HLA
DQB1*15:01 and DQB1*06:02 genes have been shown to
be associated with narcolepsy, and additional genes may
be involved13. Another recent GWAS study, using Japa-
nese individuals, identified some genomic loci related to
narcolepsy outside of the major histocompatibility com-
plex (MHC) region, such as CPT1B, TCRA, and P2RY1112.
Capitalizing on the much higher prevalence of narcolepsy
in the Japanese population (0.16–0.18%)14 compared to
the Caucasian population (0.02–0.06%)15, and using the
previous Japanese GWAS study of narcolepsy as a dis-
covery cohort, we investigated a possible genetic asso-
ciation between ADHD traits and narcolepsy in our birth
cohort sample from the HBC study. We also conducted a
polygenic risk analysis of ADHD traits using a summary
from the previous GWAS study of essential hypersomnia
(EHS), another highly heritable sleep disorder16, con-
ducted in a Japanese population17. They identified
genome-wide significance in single nucleotide poly-
morphism (SNP) on the CRAT gene located in 9q34.1117.
Although there has been no direct evidence showing the
high-concordance rate in twins and familial accumulation
of EHS and narcolepsy, it has been reported that these
disorders share several susceptibility genes16, and ~40% of
the heritability of EHS was explained by the genetic
background of narcolepsy12.
Furthermore, in order to learn more about the common
biological mechanisms underlying ADHD and narcolepsy,
a gene-set enrichment analysis was performed.
Methods
Participants
The discovery cohort for narcolepsy consisted of 409
patients with narcolepsy-cataplexy (narcolepsy type 1:
NT1) and 1562 healthy controls. The discovery cohort for
EHS was 125 EHS patients without HLA-DQB1*06:02
and 562 controls without HLA-DQB1*06:02. Details are
available on the NBDC Human Database (https://
biosciencedbc.jp/en/). The target population from the
HBC study included infants (n= 876) born between
December 2007 and June 2011. Recruitment procedures
are fully described elsewhere18. The study procedures
were approved by the Hamamatsu University School of
Medicine and the University Hospital Ethics Committee
(research ID:17-037 and 19-145). Written informed con-
sent was obtained from each caregiver for his/her infant’s
participation. Individuals with intellectual disability
(FSIQ < 80, n= 66), measured by Wechsler Preschool and
Primary Scale of Intelligence (WPPSI), were excluded
from the analysis. Also, individuals with parents of non-
Japanese descent (n= 8) were removed from the study to
minimize the effect of population stratification. This study
followed the STrengthening the Reporting of OBserva-
tional studies in Epidemiology (STROBE) reporting
guideline.
Measurement
ADHD traits were ascertained by interview at age 8
using the Japanese version of the ADHD-RS, previously
confirmed for its validity and reliability19. ADHD-RS
consists of two subscales: inattention (nine items) and
hyperactivity-impulsivity (nine items). Each item was
rated from 0 (never or rarely) to 3 (very often). The sum of
raw scores for inattention, hyperactivity-impulsivity
domains, and total scores were converted to percentile
scores using the scoring procedure provided in the
manufacture’s manual20. Full-scale IQ was measured
using the Japanese version of the WPPSI, a reliable and
child-friendly measure of cognitive development, admi-
nistered at age 4. All psychological evaluations were
conducted by trained psychologists.
Genotyping, quality control, and imputation
Genotyping was conducted using Japonica array,
designed specifically for 650,000 SNP for a Japanese
population21. In brief, the quality controls for retaining
SNPs and individuals were as follows: missing data for
SNP < 0.02, Pi-hat calculated by pairwise identify-by-
descent (IBD) analysis <0.2, SNP Hardy Weinberg equi-
librium of p > 10−6, and minor allele frequency > 0.01.
Seventy-six individuals were removed from the analysis as
“related individuals” by IBD analysis. Genotyping impu-
tation was performed using BEAGLE 5.0 to the 1000
Genome Project reference panel phase 3 of the Japanese
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population22. SNPs with an imputation INFO score <0.8
were excluded. We also excluded SNPs located within the
MHC region because of high linkage equilibrium in this
region. The number of SNPs analyzed for PRS was
5,606,655.
PRS analysis
We used PRSice-2 to generate PRS, according to the
developers’ protocol23. The summary GWAS data used to
determine the PRS for narcolepsy and EHS was obtained
from the NBDC Human Database (https://humandbs.
biosciencedbc.jp/en/). To account for population stratifi-
cation, we included four principle components (PCs). The
PCs were calculated based on the pruned data with
PLINK 1.924. The criteria for SNP clumping was pairwise
LD r2 < 0.1 within the 1Mb window. PRSs were calculated
with different P-value thresholds at 0.05, 0.05, 0.1, 0.5, and
1. Standardized PRS scores (mean= 0 and standard
deviation= 1) were used for the analyses.
Gene-set enrichment analysis
Gene-set enrichment analyses were conducted using
PRSet implemented in PRSice-2 software23. Gene-sets
collections were obtained from the MSigDB database, and
GO gene sets (c5) were used for the analyses (http://
software.broadinstitute.org/gsea/msigdb/index.jsp). A
total GO gene sets used for analysis was 7350. The P-
value threshold for PRSet was set at 1 since gene-set PRSs
containing a small portion of SNPs may be unrepre-
sentative of the whole gene-sets25. The obtained P-value
was corrected for 10,000 permutation tests, and the sig-
nificance was set at 0.05.
Genetic correlation analysis
Genetic correlations (rg) between narcolepsy and EHS
were calculated using LD (linkage disequilibrium) Score
regression26. Pre-computed LD scores for the East Asian
population from the 1000 Genomes Project were used in
the analysis (LD scores available on https://github.com/
bulik/ldsc) and the summary statistics from the NBDC
Human Database was used. Genetic correlation between
ADHD and narcolepsy was analyzed using the recent
large ADHD GWAS study2. Since the difference in the
ethnic population between ADHD and narcolepsy GWAS
study, we utilized the “Popcorn” program, which can
calculate trans-ethnic genetic correlation27.
Results
PRS analysis
Participant characteristics are summarized in Table 1. A
total of 726 participants (373 males, 353 females) were
analyzed. The narcolepsy PRS was significantly associated
with ADHD traits at various P-value thresholds either in
the hyperactivity (e.g., P-value threshold < 0.05, β [SE],
5.815 [1.774]; P= 0.002), inattentive domains (e.g., P-value
threshold < 0.05, β [SE], 5.734 [1.761]; P= 0.004) and total
score (e.g., P-value threshold < 0.05, β [SE], 6.496 [1.676];
P= 0.001) (Table 2, Fig. 1a, b, Supplemental figure). EHS
PRS was not associated with ADHD traits at any P-value
threshold analyzed (e.g., P-value threshold < 0.05), in the
hyperactivity domain (β [SE], 2.206 [1.726]; P= 0.2088)
and inattentive domain (β [SE], 2.025 [1.715]; P= 0.3753);
total score (β [SE], 1.903 [1.649]; P= 0.4174) (Table 3).
Gene-set enrichment analysis
Gene-set enrichment analyses found that several gene-
sets, such as “dopaminergic neuron differentiation” (GO:
0071542; β [SE], −5.680 [1.872]; P= 0.0034) and “inter-
leukin 6 production” (GO: 0032635; β [SE], 6.007 [1.834];
Table 1 Sample characteristics of children and their
parents in the study.
n (%)
Gender
Male 373 (51.3)
Female 353 (48.7)
Ethnicity
Japanese 726 (100)
Small for gestational age
<10th percentile 43 (5.9)
10th–100th percentile 683 (94.1)
Paternal education
<12 years 62 (8.5)
12 years and longer 664 (91.5)
Maternal education
<12 years 38 (5.3)
12 years and longer 684 (94.3)
Mean (SD)
Birthweight (g) 2940.5 (438.8)
Gestational age at birth (weeks) 38.9 (1.6)
Paternal age at birth (years) 33.2 (5.8)
Maternal age at birth (years) 31.5 (5.1)
Household income (million JPY) 6.0 (2.8)
ADHD-RS percentile
Hyperactivity 52.8 (25.8)
Inattention 50.4 (26.4)
Total 52.3 (29.3)
IQ (WPPSI:FSIQ) 103.3 (17.3)
SD standard deviation, JPY Japanese Yen, ADHD-RS attention deficit hyper-
activity disorder rating scale, IQ intelligent quotient, WPPSI Wechsler Preschool
and Primary Scale of Intelligence, FSIQ Full Scale IQ.
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Table 2 Association of narcolepsy PRS and ADHD traits.
ADHD-RS items P-value threshold Number of SNPs R2 Beta SE P-valuea
Hyperactivity 0.01 2286 0.011 2.737 1.857 0.146
0.05 8854 0.078 5.815 1.774 0.002*
0.1 15124 0.062 4.907 1.795 0.013*
0.5 46558 0.050 4.07 1.838 0.033*
1 63954 0.046 3.668 1.805 0.041*
Inattention 0.01 2286 0.011 2.753 1.8437 0.227
0.05 8854 0.095 5.734 1.761 0.004*
0.1 15124 0.070 4.167 1.792 0.062
0.5 46558 0.063 3.627 1.83 0.102
1 63954 0.060 3.312 1.795 0.105
Total score 0.01 2286 0.018 3.357 1.767 0.112
0.05 8854 0.110 6.496 1.676 0.001*
0.1 15124 0.087 5.378 1.703 0.008*
0.5 46558 0.063 3.893 1.755 0.066
1 63954 0.059 3.668 1.723 0.079
PRS polygenic risk score, ADHD attention deficit hyperactivity disorder, ADHD-RS attention deficit hyperactivity disorder rating scale, SNP single nucleotide
polymorphism, SE standard error.
aP-values were corrected using 10,000 permutation tests. * Statistically significant after multiple testing correction.
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Fig. 1 Quantile plot of Narcolepsy PRS and ADHD traits. a Quantile plot of Narcolepsy PRS and ADHD traits (hyperactivity). This figure provides
the percentile of ADHD-RS hyperactivity score against the strata of polygenic risk score for narcolepsy after the cohort was divided into 100 groups.
The error bars mean standard deviation. b Quantile plot of Narcolepsy PRS and ADHD traits (inattention). This figure provides the percentile of ADHD-
RS inattention score against the strata of polygenic risk score for narcolepsy after the cohort was divided into 100 groups. The error bar means
standard deviation. ADHD attention deficit hyperactivity disorder, PRS polygenic risk score.
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P= 0.0006), were associated with hyperactivity traits and
narcolepsy (Table 4), while gene-sets, such as “iron
coordination entity transport” (GO: 190167; β [SE],
−6.686 [1.795]; P= 0.0002) and “positive regulation of
glial cell differentiation” (GO: 0045687; β [SE], 5.457
[1.808]; P= 0.00350) were significantly associated with
both inattention traits and narcolepsy (Table 5).
Exploratory analysis using the Comparative Tox-
icogenomics Database (http://ctdbase.org) indicated that
several compounds, including N-acetylcysteine, baicalein,
and fatty acids, were modulators for hyperactivity-related
gene ontologies, and dextroamphetamine was a mod-
ulator for inattention-related gene-sets.
Genetic correlation analysis
LD score regression analysis using summary data of
previous GWAS studies of narcolepsy and EHS showed
that these disorders were positively correlated (rg [SE]=
0.500 [0.062], P= 4.42 × 10−16). Genetic correlation ana-
lysis using summary data of Japanese narcolepsy GWAS
and ADHD GWAS conducted by psychiatric genomics
consortium showed that these disorders were also posi-
tively correlated (rg [SE]= 0.165 [0.114], P= 1.11 × 10
−5).
Discussion
To our knowledge, this is the first study that has
examined the genetic association of ADHD traits and
narcolepsy. We found that the genetic risk for narcolepsy
has a significant association with ADHD traits using data
from the general population. Specifically, both hyper-
activity and inattention traits were significantly associated
with narcolepsy PRS, suggesting that these disorders have
a close genetic association. Genetic correlation analysis
using previous GWAS studies of narcolepsy and ADHD
also support the present findings.
Managing EDS among individuals with ADHD is
important since EDS is directly related to academic per-
formance and teachers’ ratings of classroom behavior and
performance28. However, EDS in ADHD has usually been
considered the result of delayed sleep phase or poor
quality of sleep29, meaning that the nature of the rela-
tionship and the possibility of common underlying biolo-
gical determinants have not been investigated. Based on
the present findings, clinicians, caregivers, and teachers
should be informed that there could be a genetic vulner-
ability for daytime sleepiness in children and adolescents
with ADHD. Demontis et al.2 found a significant associa-
tion between ADHD and insomnia. Their finding is not
directly linked to our present findings; however, it is also
known that subjects with narcolepsy frequently experience
disrupted nighttime sleep, which could exacerbate EDS30.
Future studies examining the relationship between genetic
risks for narcolepsy and the quality of nighttime sleep in
the present population is needed.
Table 3 Association of essential hypersomnia PRS and ADHD traits.
ADHD-RS items P-value threshold Number of SNP R2 Beta SE P-valuea
Hyperactivity 0.01 1839 0.026 0.788 1.900 0.6732
0.05 7501 0.034 2.206 1.726 0.2088
0.1 13323 0.040 2.955 1.760 0.1021
0.5 43288 0.032 2.094 1.772 0.2421
1 60966 0.031 1.913 1.756 0.2786
Inattention 0.01 1839 0.045 1.053 1.883 0.7773
0.05 7501 0.050 2.025 1.715 0.3753
0.1 13323 0.052 2.249 1.753 0.3218
0.5 43288 0.049 1.851 1.760 0.4437
1 60966 0.049 1.749 1.744 0.4793
Total score 0.01 1839 0.039 0.665 1.812 0.9265
0.05 7501 0.045 1.903 1.649 0.4174
0.1 13323 0.052 2.73 1.682 0.1983
0.5 43288 0.047 2.228 1.690 0.3234
1 60966 0.048 2.285 1.674 0.2977
PRS polygenic risk score, ADHD attention deficit hyperactivity disorder, ADHD-RS attention deficit hyperactivity disorder rating scale, SNP single nucleotide
polymorphism, SE standard error.
aP-values were corrected for multiple testing using 10,000 permutation tests.
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Interestingly, we identified pathways related to common
molecular mechanisms underlying ADHD traits and
narcolepsy. Several gene-sets were identified as having an
association with ADHD symptoms and narcolepsy in the
gene-set enrichment analysis. The results are intriguing
and bear further study. Notably, gene-sets relevant to
dopaminergic signaling were associated with both dis-
orders, consistent with the recognition that most medi-
cations currently used for ADHD, narcolepsy and EHS are
thought to increase synaptic dopamine9. Immune systems
have long been implicated in the mechanism of narco-
lepsy31, but recent evidence suggests that neuroin-
flammation is involved in the development of ADHD as
well32. Furthermore, neuronal inflammation has been
shown to not only alter levels of monoamine neuro-
transmitters, including dopamine and noradrenaline32 but
also to affect the expression of histamine and orexin33,34,
which are promising targets for novel drug treatments for
narcolepsy. In addition, gene-sets relevant to glial cell
function and iron transport were found to be associated
with both ADHD traits and narcolepsy. In line with these
findings, recent genetics and brain imaging studies have
suggested that altered myelin and oligodendrocyte related
signaling were implicated in both ADHD2,35 and narco-
lepsy36,37. Changes in iron homeostasis have been shown
to affect dopamine synthesis38 and also been proposed as
a biological mechanism for ADHD39,40. Although there
has been no direct evidence of iron deficiency in narco-
lepsy subjects, restless leg syndrome (RLS) was shown to
be more prevalent in subjects with narcolepsy compared
to general population41. The exact pathophysiology of
RLS is still unclear. However, it has been repeatedly
reported that RLS is also common in ADHD subjects42,
and iron homeostasis and dopamine signaling have been
implicated in the development of this condition43. These
gene-set enrichment analyses suggest that ADHD traits
and narcolepsy share common biological mechanisms
such as dopamine signaling, immune system regulation,
glial cell function, and iron homeostasis.
We did not find a significant association between EHS
PRS and ADHD traits, although genetic correlation ana-
lysis showed that narcolepsy and EHS were genetically
Table 4 Gene-sets significantly enriched for hyperactivity traits and narcolepsy.
Gene-set R2 Beta SE Number of SNPs P-valuea
Apoptotic process 0.102 −6.778 1.691 4379 0.0003
Transition metal ion transport 0.082 −5.986 1.759 267 0.0006
Regulation of neurotransmitter levels 0.088 −6.726 1.863 1133 0.0007
Interleukin 6 production 0.078 6.007 1.834 265 0.0011
Heme transport 0.075 −5.865 1.835 26 0.0013
Phosphate ion transmembrane transport 0.078 −6.212 1.894 20 0.0014
Negative regulation of tumor necrosis factor secretion 0.074 −5.930 1.888 11 0.0018
Negative regulation of bone development 0.072 5.599 1.812 26 0.0023
Iron ion transport 0.070 −5.598 1.865 127 0.0027
Positive regulation of reactive oxygen species metabolic process 0.070 −5.342 1.776 102 0.0027
Cerebellar cortex development 0.073 −6.279 2.008 143 0.0028
Dopaminergic neuron differentiation 0.071 −5.680 1.872 68 0.0034
Signal release from synapse 0.076 −5.984 1.862 700 0.0034
Midbrain development 0.068 −5.539 1.892 162 0.0037
Regulation of nitric oxide mediated signal transduction 0.067 −5.417 1.864 38 0.0037
Cellular response to oxidative stress 0.074 −6.202 1.961 650 0.0039
Interferon alpha production 0.066 5.216 1.814 48 0.0042
Positive regulation of tumor necrosis factor superfamily Cytokine production 0.066 5.052 1.762 157 0.0044
Positive regulation of interleukin 12 production 0.066 5.228 1.816 79 0.0044
Positive regulation of interleukin 13 production 0.067 5.171 1.791 26 0.0047
SNP single nucleotide polymorphism, SE standard error.
aP-values were corrected for 10,000 permutation tests.
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correlated. One possible explanation for this is that the
sample size of the discovery cohort of EHS (Case= 125,
control= 1562) was smaller than that of narcolepsy (Case
= 409, control= 1562). Thus the calculated EHS PRS did
not have adequate power for detecting association with
ADHD traits in this study.
Our exploratory analysis using gene-sets enriched in
ADHD traits and narcolepsy suggests that medications
currently used for ADHD and narcolepsy, such as the
psychostimulants, target common biological pathways
underlying both disorders. We also found that N-acet-
ylcysteine, baicalein, and fatty acid could be investigated
as novel therapeutic agents for both ADHD and narco-
lepsy symptoms. Although very preliminary, reports sug-
gest the efficacy of N-acetylcysteine for both hyperactivity
and inattention symptoms of ADHD44,45. N-
acetylcysteine has also been shown to be protective for
dopamine neurons46. Baicalein is a flavonoid purified
from the plant Scutellaria baicalensis. A recent study
using an animal model of ADHD demonstrated the effi-
cacy of core ADHD symptoms by regulating dopaminer-
gic signaling in the brain47. More recently, the reduction
of fatty acids in the blood48 among children and adoles-
cents with ADHD, and similarly, the efficacy of a high
dose of eicosapentaenoic acid (EPA) for ADHD symptoms
have been reported49. Future clinical trials using both
existing and novel compounds for ADHD and narcolepsy
are warranted.
Limitations
There are some limitations to this study. First, we tar-
geted a general population, leveraging our longitudinal
birth cohort HBC. The cohort is representative of the
general population, and thus caution is needed when
applying the findings to clinically diagnosed ADHD
patients. Second, the original GWAS study of narcolepsy
included individuals only with NT1, but not narcolepsy
type 2 (NT2), which lacks cataplexy. It is unknown whe-
ther the genetic architectures of NT1 and NT2 are the
same. Thus, a future GWAS study using NT2 is needed.
Third, the prevalence of narcolepsy is known to be higher
in the Japanese than the Caucasian population, and future
studies using different ethnic populations are needed to
replicate these findings.
Table 5 Gene-sets significantly enriched for inattention traits and narcolepsy.
Gene-set R2 Beta SE Number of SNPs P valuea
Heme transport 0.125 −7.488 1.789 260 0.0001
Iron coordination entity transport 0.109 −6.686 1.795 29 0.0002
Negative regulation of cation channel activity 0.096 6.190 1.873 122 0.0008
Regulation of chromatin binding 0.097 −6.327 1.896 49 0.0009
Regulation of presynapse organization 0.091 5.510 1.765 198 0.0010
Postsynaptic specialization organization 0.096 5.917 1.791 302 0.0014
Transition metal ion transport 0.090 −5.468 1.755 267 0.0023
Positive regulation of glial cell differentiation 0.088 5.457 1.808 101 0.0035
Epithelial mesenchymal cell signaling 0.089 5.408 1.774 4 0.0035
Postsynaptic specialization assembly 0.085 5.098 1.745 229 0.0035
Vitamin d metabolic process 0.083 −5.228 1.825 54 0.0040
mRNA cleavage involved in mRNA processing 0.081 −4.676 1.699 13 0.0058
Positive regulation of oligodendrocyte differentiation 0.080 4.848 1.785 62 0.0062
Regulation of oligodendrocyte differentiation 0.081 5.027 1.807 91 0.0066
Formation of cytoplasmic translation initiation complex 0.078 −4.867 1.828 15 0.0070
Radial glial cell differentiation 0.078 4.809 1.816 29 0.0072
Response to corticotropin releasing hormone 0.080 −5.403 1.987 9 0.0075
Multicellular organismal movement 0.080 5.452 1.994 142 0.0078
Transforming growth factor beta secretion 0.077 4.421 1.689 12 0.0083
Synaptic membrane adhesion 0.078 4.795 1.800 245 0.0087
SNP single nucleotide polymorphism, SE standard error.
aP-values were corrected for 10,000 permutation tests.
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Conclusion
In this study, using PRS analysis, we found that genetic
risk factors for narcolepsy contribute to ADHD traits in
the general Japanese population, and identified common
molecular pathways in these conditions. We hope that
this discovery will be replicated and lead to an under-
standing that EDS in ADHD might have a biological
foundation.
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